Emalex Biosciences Announces $250 Million Financing to Advance New Drug for Tourette Syndrome

Chicago, IL, November 3, 2022 (PRNewswire) -- Emalex Biosciences announced the closing of an upsized and oversubscribed $250 million Series D funding round that will fund a Phase 3 clinical trial and potential commercialization of a new class of drug for patients with Tourette Syndrome.

Read full article here.